---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-024187"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T09:25:09.126280+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Terns Pharmaceuticals appoints Robert Azelby to board; Carl Gordon resigns

## Summary
- Robert Azelby appointed to Board as Class I director effective Feb 20, 2025, and joins Compensation Committee.
- Carl Gordon resigned from Board effective Feb 20, 2025 after over seven years; departure not due to disagreement.
- Azelby brings 25+ years biopharma experience including CEO roles at Eliem Therapeutics and Alder BioPharmaceuticals.
- Azelby received option to purchase 90,000 shares vesting over three years under non-employee director compensation plan.
- Company highlights TERN-701 for chronic myeloid leukemia and obesity programs approaching clinical readouts.

## SEC filing metadata
- accession: 0000950170-25-024187
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/0000950170-25-024187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/tern-20250220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-024187
- JSON: https://secwatch.observer/filing/0000950170-25-024187.json
- Plain text: https://secwatch.observer/filing/0000950170-25-024187.txt

## Source-grounded claims
- claim_id: 7ea0624059
  claim: Carl Gordon resigned as Director at Terns Pharmaceuticals, Inc..
  evidence_excerpt: On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/0000950170-25-024187-index.htm
- claim_id: c96272df14
  claim: Robert Azelby was appointed as Director at Terns Pharmaceuticals, Inc..
  evidence_excerpt: On February 20, 2025, the Board appointed and elected Robert Azelby as a member of the Board, effective as of February 20, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/0000950170-25-024187-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.